SCHEMBL5097227

SCHEMBL5097227

CCN(CC)CCC(=O)NC(C)C[O]

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TERT O14746 7/20 0.41
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
TSHR P16473 1/20 0.37
ALDH1A1 P00352 2/20 0.37
POLB P06746 1/20 0.37
GAA P10253 1/20 0.37
MAPT P10636 1/20 0.37
DNMT1 P26358 1/20 0.37
RAD52 P43351 1/20 0.37
SMARCA2 P51531 1/20 0.37
FAAH O00519 1/20 0.35
MAPK1 P28482 1/20 0.35
PAOX Q6QHF9 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
LMNA P02545 1/20 0.34
HPGD P15428 1/20 0.33
KCNK3 O14649 1/20 0.33
THRB P10828 1/20 0.33
CNR2 P34972 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5097235 0.85 CNR2 (0.45) TERTMEN1KMT2ATSHRALDH1A1
SCHEMBL7137889 0.82 MEN1 (0.52) TERTMEN1KMT2ATSHRALDH1A1
SCHEMBL27721819 0.76 TERT (0.42) TERTMEN1KMT2ATSHRALDH1A1
SCHEMBL13756157 0.74 FAAH (0.47) MEN1KMT2AALDH1A1FAAHMAPK1
SCHEMBL5091083 0.73
SCHEMBL13756041 0.73 FAAH (0.46) MEN1KMT2AALDH1A1FAAHMAPK1
SCHEMBL13756164 0.73 FAAH (0.46) MEN1KMT2AALDH1A1FAAHMAPK1
SCHEMBL20582915 0.72 FAAH (0.69) MEN1KMT2AALDH1A1FAAHMAPK1
SCHEMBL8165555 0.71 LMNA (0.44) TERTMEN1KMT2ATSHRALDH1A1
SCHEMBL10820664 0.71 FAAH (0.41) MEN1KMT2AALDH1A1FAAHMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1951686-B1 QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF HANMI PHARM IND CO LTD (KR) 2013-04-03 EP claimed
US-20080318950-A1 Quinazoline Derivatives as a Multiplex Inhibitor and Method For the Preparation Thereof HANMI PHARM. CO., LTD (KR) 2008-12-25 US claimed
US-8846699-B2 Quinazoline derivatives as a multiplex inhibitor and method for the preparation thereof HANMI PHARM. CO., LTD. (KR) 2014-09-30 US disclosed
EP-1951686-B1 QUINAZOLINE DERIVATIVES AS A MULTIPLEX INHIBITOR AND METHOD FOR THE PREPARATION THEREOF HANMI PHARM IND CO LTD (KR) 2013-04-03 EP disclosed
CN-101304978-B Quinazoline derivative as multi-component inhibitor, pharmaceutical composition and application HANMI PHARM IND CO LTD 2012-12-26 CN disclosed
US-20080318950-A1 Quinazoline Derivatives as a Multiplex Inhibitor and Method For the Preparation Thereof HANMI PHARM. CO., LTD (KR) 2008-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318950-A1 Quinazoline Derivatives as a Multiplex Inhibitor and Method For the Preparation Thereof ABL1, JAK1, BTK TERT 3899/4885MEN1 1070/4885KMT2A 1033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.